Американское общество гирудотерапии

Production and functional characteristics of a novel hirudin variant with better anticoagulant activities than bivalirudin

Research article published in Journal of enzyme inhibition and medicinal chemistry (2025)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportРазработка лекарственных препаратовGe L et al. · Journal of enzyme inhibition and medicinal chemistry, 2025

Abstract

Current antithrombotic therapies face dual constraints of bleeding complications and monitoring requirements. Although natural hirudin provides targeted thrombin inhibition, its clinical adoption is hindered by sourcing limitations. This study developed a recombinant hirudin variant HMg (rHMg) with enhanced anticoagulant activity through genetic engineering and established cost-effective large-scale production methods. The synthesised HMg gene was expressed in E. coli BL21 via a pET vector plasmid, followed by nickel-affinity purification. Systematic evaluations demonstrated rHMg's antithrombin activity of 9573 ATU/mg, dose-dependent prolongation of APTT/PT/TT. It has superior thrombin inhibition with the IC50 and Ki values were 2.8 and 0.323 nM respectively compared to FDA approved drug bivalirudin (p < 0.001). The high-yield prokaryotic expression of rHMg with enhanced anticoagulant efficacy provides a novel strategy for developing affordable antithrombotic drugs, showing significant potential for cardiovascular disease management.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHirudinsAnticoagulantsPeptide FragmentsHumansDose-Response Relationship, DrugStructure-Activity RelationshipRecombinant ProteinsThrombinMolecular StructureEscherichia coli

Резюме

Production and functional characteristics of a novel hirudin variant with better anticoagulant activities than bivalirudin.

Почему это важно для гирудотерапии

This study reports the development of a recombinant hirudin variant, rHMg, with enhanced anticoagulant activity relative to bivalirudin, produced via E. coli expression and nickel-affinity purification. The abstract states that rHMg exhibited antithrombin activity of 9573 ATU/mg, dose-dependent prolongation of APTT/PT/TT, and superior thrombin inhibition with IC50 and Ki values of 2.8 and 0.323 nM, respectively, compared to bivalirudin. The authors frame this as a strategy for affordable antithrombotic drug development. The topic is relevant to hirudotherapy insofar as the starting point is natural hirudin, but the abstract does not specify its biological source and the work concerns a synthesized recombinant protein rather than live leeches. Findings would require further validation beyond the reported evaluations.

Цитирование

Production and functional characteristics of a novel hirudin variant with better anticoagulant activities than bivalirudin

Ge L et al. · Journal of enzyme inhibition and medicinal chemistry, 2025

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.